Unicycive Therapeutics, Inc., (UNCY): Price and Financial Metrics
UNCY Price/Volume Stats
| Current price | $1.07 | 52-week high | $1.82 |
| Prev. close | $1.09 | 52-week low | $0.47 |
| Day low | $1.04 | Volume | 231,000 |
| Day high | $1.13 | Avg. volume | 358,272 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $0.95 | Market Cap | 37.19M |
UNCY Stock Price Chart Interactive Chart >
Unicycive Therapeutics, Inc., (UNCY) Company Bio
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest UNCY News From Around the Web
Below are the latest news stories about UNICYCIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate UNCY as an investment opportunity.
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on DialysisStudy will Evaluate 60 Participants with Results Expected in Q2 2024LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC). OLC is a next-generation lanthanum-based phosp |
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023. Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Presentation: Monday, December 4, 2023 at 3:30 pm ET Boca Rat |
Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net loss: US$4.41m (loss... |
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business UpdateReached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a bus |
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug App |
UNCY Price Returns
| 1-mo | -24.65% |
| 3-mo | 23.49% |
| 6-mo | 23.02% |
| 1-year | -33.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 23.31% |
| 2023 | 60.69% |
| 2022 | -73.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...